Develops immunotherapy treatments for cancer and infectious diseases, focusing on T-cell therapies.
TC Biopharm (Holdings) Plc is a clinical-stage biopharmaceutical company dedicated to advancing immunotherapy treatments leveraging its innovative allogeneic gamma delta T cell platform. Headquartered in Motherwell, United Kingdom, the company focuses on developing transformative therapies for critical medical conditions.
At the forefront of TC Biopharm's pipeline is OmnImmune, an unmodified cell therapy targeted at treating acute myeloid leukemia. Additionally, the company is developing ImmuniStim, another unmodified cell therapy aimed at addressing the urgent global challenge posed by COVID-19. These therapies underscore TC Biopharm's commitment to harnessing the potential of gamma delta T cells in combating serious diseases.
Founded in 2013, TC Biopharm has rapidly emerged as a leader in the field of immunotherapy. With a strong emphasis on research and development, the company continues to innovate and explore new avenues to enhance the therapeutic landscape for patients worldwide.